EyePoint Pharmaceuticals Inc.

About EyePoint Pharmaceuticals Inc.

EyePoint is dedicated to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, with a focus on science, innovation, and preserving vision.

Products & Services

Durasert E™:A proprietary technology enabling sustained intraocular delivery to preserve vision with less burden for retinal diseases.

DURAVYU™ (EYP-1901):An investigational treatment for VEGF-mediated retinal diseases, combining vorolanib (a tyrosine kinase inhibitor) with bio-erodible Durasert E™ for sustained delivery. Not yet FDA-approved.

Durasert®:A proven technology safely administered to thousands of patients' eyes across four FDA-approved products.

Specialties

Retinal disease therapeutics Intraocular drug delivery VEGF-mediated disease treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering of Common Stock T: - FT: Public Offering of Common Stock	A: 150000000 MR: - FA: $150 million FAN: 150000000	D: 2025-10-14 FD: 2025-10-14	4 investors
2	RT: Public Offering T: - FT: Public Offering	A: 150000000 MR: - FA: approximately $150 million FAN: 150000000	D: 2025-10-14 FD: 2025-10-14	4 investors
3	RT: Public Offering T: - FT: Public Offering	A: 161000000 MR: - FA: $161.0 million FAN: 161000000	D: 2024-10-31 FD: 2024-10-31	6 investors
4	RT: Public Offering T: - FT: Public Offering	A: 140000000 MR: - FA: approximately $140.0 million FAN: 140000000	D: 2024-10-29 FD: 2024-10-29	6 investors
5	RT: Public Offering of Common Stock T: - FT: Public Offering of Common Stock	A: 100000000 MR: - FA: $100 million FAN: 100000000	D: 2024-10-28 FD: 2024-10-28	3 investors
6	RT: Public Offering T: - FT: Public Offering	A: 230000000 MR: - FA: approximately $230.0 million FAN: 230000000	D: 2023-12-08 FD: 2023-12-08	6 investors
7	RT: Public Offering T: - FT: Public Offering	A: 200000000 MR: - FA: approximately $200.0 million FAN: 200000000	D: 2023-12-05 FD: 2023-12-05	6 investors
8	RT: Public Offering T: - FT: Public Offering	A: 175000000 MR: - FA: $175 million FAN: 175000000	D: 2023-12-04 FD: 2023-12-04	3 investors

Public Offering of Common Stock Latest

2025-10-14

$150.0M

4 investors (Pro only)

Public Offering 2025-10-14

$150.0M

Public Offering 2024-10-31

$161.0M

View 7 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

U

Udaya

Director of Financial Planning and Analysis

G

George

Manager, Manufacturing Operations

S

Samantha

Senior Clinical Trial Manager

J

Jay S. Duker

President & CEO and Board Director

G

George O. Elston

Executive Vice President, Chief Financial Officer

R

Ramiro Ribeiro

Chief Medical Officer

View 27 more team members with Pro

Unlock Full Team Directory

Recent News